Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.67 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770278 | 0.90 | OPRM1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13250907 | 0.88 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL4730550 | 0.87 | OPRD1 (0.72) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL10243104 | 0.86 | OPRM1 (0.65) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13656736 | 0.85 | OPRM1 (0.46) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL16922125 | 0.83 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13998951 | 0.83 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3476558 | 0.83 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3475526 | 0.83 | OPRM1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8769434 | 0.82 | OPRM1 (0.67) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176885-A1 | Improved Pharmacokinetics; side effects reduction; codrugs are covalently bound by a linker that is capable of cleavage in the body; analgesics | UNIVERSITY OF KENTUCKY (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176885-A1 | Improved Pharmacokinetics; side effects reduction; codrugs are covalently bound by a linker that is capable of cleavage in the body; analgesics | OPRK1, CNR1, CNR2 | OPRM1 6/4885OPRK1 1/4885OPRD1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.